The company has not filed an annual or quarterly report since its Q2 FY2023 10-Q, filed Aug 2, 2023. Its latest SEC filing is a 15-12G from Sep 18, 2023.
10-Q for Q2 FY2023, filed Aug 2, 2023
The sections below describe the company as of the FY2022 annual report.
Develops antibody-based cancer therapies aimed at the immune-suppressing environment around tumors, for cancer patients and pharmaceutical partners.
10-K for FY2022, filed Mar 9, 2023
Novartis and GSK are pharmaceutical partners with exclusive licenses to develop and commercialize antibody programs.
10-K for FY2022, filed Mar 9, 2023In addition to our internal programs, we have two programs, NZV930 and GSK4381562, which are exclusively licensed to Novartis Institutes…View ↗
In January 2016, we granted Novartis a worldwide exclusive license to research, develop, manufacture, and commercialize NZV930. NZV930 is…View ↗
In December 2020, we granted GSK an exclusive license to the worldwide development and commercialization rights for GSK4381562. GSK4381562…View ↗
10-Q for Q2 FY2023, filed Aug 2, 2023
−$28.2MView ↗
8-K, filed Sep 8, 2023
REDWOOD CITY, Calif., September 8, 2023 — Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the closing of the previously…View ↗
8-K, filed Jun 16, 2023
On June 15, 2023, Surface Oncology, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger…View ↗
Paused adenosine-pathway work
The earlier report described a company-owned antibody program aimed at an adenosine-producing enzyme and planned clinical testing; the latest says development is paused while Surface seeks partners.
10-K for FY2019, filed Mar 10, 2020 10-K for FY2022, filed Mar 9, 2023SRF617 inhibits CD39, an enzyme critical both to the production of adenosine and the breakdown of ATP. We believe targeting CD39 will not…View ↗
Our third clinical-stage program, SRF617 is an antibody designed to inhibit cluster of differentiation-39, or CD39. CD39 is a critical…View ↗
GSK licensing
Alongside the Novartis collaboration described earlier, the latest report describes an exclusive antibody license to GSK.
10-K for FY2019, filed Mar 10, 2020 10-K for FY2022, filed Mar 9, 2023We have assembled an outstanding team, including our world-class scientific advisory board, to execute on our mission to create…View ↗
In December 2020, we granted GSK an exclusive license to the worldwide development and commercialization rights for GSK4381562. GSK4381562…View ↗
Competes with Bristol-Myers Squibb, Shionogi, AbbVie, Bayer, LaNova, Immunophage, Compugen, Jiangsu Hengrui, Arcus Biosciences, AstraZeneca, Corvus Pharmaceuticals, Innate Pharma, iTeos, Trishula Therapeutics, Elpiscience, Shanghai Junshi, I-Mab, Portage Biotech, Agenus, and Exscientia
10-K for FY2022, filed Mar 9, 2023Programs in development targeting CCR8, including those by Bristol-Myers Squibb Company, Gilead/Jounce, Shionogi, AbbVie, Bayer, LaNova and…View ↗
Loading...
